Abbott India Limited (NSE:ABBOTINDIA) — Market Cap & Net Worth
Market Cap & Net Worth: Abbott India Limited (ABBOTINDIA)
Abbott India Limited (NSE:ABBOTINDIA) has a market capitalization of $5.85 Billion (Rs540.48 Billion) as of May 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #3239 globally and #147 in its home market, demonstrating a 0.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Abbott India Limited's stock price Rs25435.00 by its total outstanding shares 21249302 (21.25 Million). Analyse ABBOTINDIA cash flow metrics to see how efficiently the company converts income to cash.
Abbott India Limited Market Cap History: 2015 to 2026
Abbott India Limited's market capitalization history from 2015 to 2026. Data shows growth from $1.29 Billion to $5.85 Billion (16.50% CAGR).
Index Memberships
Abbott India Limited is a constituent of 8 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY PHARMA
CNXPHARMA
|
$86.64 Billion | 6.75% | #8 of 20 |
|
NIFTY100 EQUAL WEIGHT
NIFTY100EW
|
$1.79 Trillion | 0.33% | #67 of 99 |
|
NIFTY 500
NIFTY500
|
$3.11 Trillion | 0.19% | #135 of 500 |
|
NIFTY HEALTHCARE
NIFTYHEALTHCARE
|
$102.93 Billion | 5.68% | #10 of 20 |
|
NIFTY MIDCAP 150
NIFTYMIDCAP150
|
$695.80 Billion | 0.84% | #58 of 150 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$1.11 Trillion | 0.53% | #63 of 400 |
|
NIFTY MNC
NIFTYMNC
|
$231.65 Billion | 2.52% | #13 of 30 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.20 Trillion | 0.18% | #133 of 750 |
Weight: Abbott India Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Abbott India Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Abbott India Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.10x
Abbott India Limited's market cap is 0.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.47x
Abbott India Limited's market cap is 0.47 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.02 Billion | $25.78 Billion | $2.55 Billion | 0.04x | 0.40x |
| 2017 | $1.20 Billion | $28.93 Billion | $2.77 Billion | 0.04x | 0.43x |
| 2018 | $1.64 Billion | $33.00 Billion | $4.01 Billion | 0.05x | 0.41x |
| 2019 | $2.86 Billion | $36.76 Billion | $4.50 Billion | 0.08x | 0.64x |
| 2020 | $3.48 Billion | $40.91 Billion | $5.93 Billion | 0.08x | 0.59x |
| 2021 | $4.33 Billion | $43.08 Billion | $6.91 Billion | 0.10x | 0.63x |
| 2022 | $4.77 Billion | $49.10 Billion | $7.99 Billion | 0.10x | 0.60x |
| 2023 | $5.18 Billion | $53.47 Billion | $9.49 Billion | 0.10x | 0.55x |
| 2024 | $6.83 Billion | $58.47 Billion | $12.01 Billion | 0.12x | 0.57x |
| 2025 | $6.67 Billion | $64.09 Billion | $14.14 Billion | 0.10x | 0.47x |
Competitor Companies of ABBOTINDIA by Market Capitalization
Companies near Abbott India Limited in the global market cap rankings as of May 4, 2026.
Key companies related to Abbott India Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Abbott India Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Abbott India Limited's market cap moved from $1.29 Billion to $ 5.85 Billion, with a yearly change of 16.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs5.85 Billion | -12.37% |
| 2025 | Rs6.67 Billion | -2.41% |
| 2024 | Rs6.83 Billion | +32.03% |
| 2023 | Rs5.18 Billion | +8.44% |
| 2022 | Rs4.77 Billion | +10.35% |
| 2021 | Rs4.33 Billion | +24.42% |
| 2020 | Rs3.48 Billion | +21.36% |
| 2019 | Rs2.86 Billion | +75.20% |
| 2018 | Rs1.64 Billion | +36.14% |
| 2017 | Rs1.20 Billion | +18.10% |
| 2016 | Rs1.02 Billion | -20.86% |
| 2015 | Rs1.29 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Abbott India Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.85 Billion USD |
| MoneyControl | $5.85 Billion USD |
| MarketWatch | $5.85 Billion USD |
| marketcap.company | $5.85 Billion USD |
| Reuters | $5.85 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Abbott India Limited
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, … Read more